BenevolentAI Investor Presentation Deck
Our new structure delivers a tangible path to enhance
value creation
Cash runway extended to at least
July 2025, before factoring in any
new revenue
Opportunity for meaningful
revenue generation from a new
suite of Al products and portfolio
assets
Building a commercial function,
including executive leadership,
product sales and marketing, to
drive revenue growth
Increased operational focus from
two distinct business units
1. Large Language Model.
Bio Unit
BEN-8744
Ulcerative Colitis
Entering Ph. I in Q3 2023
BEN-28010
Glioblastoma Multiforme
IND ready in Q4 2023
Earlier Stage Assets
Amyotrophic Lateral Sclerosis,
Parkinson's Disease & Fibrosis
Discovery Collaboration
AstraZeneca
Paused Programmes
Under review
Tech Unit
Augmented Intelligence
Bio-Al
Trained LLMs¹
and Knowledge
Graphs
+
Data Model
Multi-modal
data
foundations
Modular use-cases
Advance
Drug Discovery
Target ID, drug
repurposing, and
others
Scale life
scientist
capabilities
Al enabling
day-to-day
workflows
Benevolent
4View entire presentation